Evaluation of six different rapid methods for nucleic acid detection of SARS‐COV‐2 virus

In the current coronavirus disease 2019 (COVID‐19) pandemic there is a mass screening of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) happening around the world due to the extensive spread of the infections. There is a high demand for rapid diagnostic tests to expedite the identification of cases and to facilitate early isolation and control spread. Hence this study evaluates six different rapid nucleic acid detection assays that are commercially available for SARS‐CoV‐2 virus detection. Nasopharyngeal samples were collected from 4981 participants and were tested for the SARS‐CoV‐2 virus by the gold standard real‐time reverse‐transcription polymerase chain reaction (RT‐PCR) method and with one of these six rapid methods of detection. Evaluation of the rapid nucleic acid detection assays was done by comparing the results of these rapid methods with the gold standard RT‐qPCR results for SARS‐COV‐2 detection. AQ‐TOP had the highest sensitivity (98%) and a strong kappa value of 0.943 followed by Genechecker and Abbot ID NOW. The POCKIT (ii RT‐PCR) assay had the highest test accuracy of 99.29% followed by Genechecker and Cobas Liat. Atila iAMP showed the highest percentage of invalid reports (35.5%) followed by AQ‐TOP with 6% and POCKIT with 3.7% of invalid reports. Genechecker system, Abbott ID NOW, and Cobas Liat were found to have the best performance and agreement when compared with the standard RT‐PCR for COVID‐19 detection. With further research, these rapid tests have the potential to be employed in large‐scale screening of COVID‐19.